Search research articles
Contact Us
Filters
Showing results (151-160 of 162) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 2020
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group
Rajen Mody, Alice L Yu, Arlene Naranjo, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2023
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group
Amy K Erbe, Mitch B Diccianni, Rajen Mody, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Frontiers in Immunology
|
June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
Amy K Erbe, Wei Wang, Patrick K Reville, et al.
Journal for Immunotherapy of Cancer
|
July 29, 2020
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study
Chiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, et al.
The New England Journal of Medicine
|
October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group
Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.
Eclinicalmedicine
|
December 8, 2025
Landscape of paediatric oncology clinical trials in Asia
Muhammad Saghir Khan, Daisuke Tomizawa, Huyung Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2019
A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Wayne L Furman, Sara M Federico, Mary Beth McCarville, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 162) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 2020
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group
Rajen Mody, Alice L Yu, Arlene Naranjo, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2023
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group
Amy K Erbe, Mitch B Diccianni, Rajen Mody, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Frontiers in Immunology
|
June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
Amy K Erbe, Wei Wang, Patrick K Reville, et al.
Journal for Immunotherapy of Cancer
|
July 29, 2020
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study
Chiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, et al.
The New England Journal of Medicine
|
October 1, 2010
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group
Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, et al.
Eclinicalmedicine
|
December 8, 2025
Landscape of paediatric oncology clinical trials in Asia
Muhammad Saghir Khan, Daisuke Tomizawa, Huyung Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2017
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2019
A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma
Wayne L Furman, Sara M Federico, Mary Beth McCarville, et al.
Page
of 17